Fig. 7: Co-mutation analysis of KYT Cohort with OS.
From: Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
a Co-mutation analysis of KYT cohort, associations between prevalent driver mutations were assessed using the Fisher’s exact method and a significant FDR-corrected p indicated by asterixis (*FDR-corrected p < 0.1). b Bar plot showing the difference in median overall survival between different KRAS mutation subtypes. * indicate p < 0.05 using log-rank test for survival. ^Wildtype: indicate no pathogenic mutations were detected.
